Palivizumab (Q33726228)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Palivizumab	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

Palivizumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Scott LJ

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Lamb HM

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

1 August 1999

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

305-11; discussion 312-3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Respiratory syncytial virus (RSV) disease and prospects for its control

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of RSV neutralizing antibodies in the treatment and prevention of respiratory syncytial virus infection in high-risk children

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The therapeutic potential of monoclonal antibodies against respiratory syncytial virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10473022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199958020-00009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33726228&oldid=2195700471"